Announcement

Amavita Research Achieves 2026 IAOCR GCSA Recertification

Independent assessment confirms continued operational excellence across all 7 modules of the global quality standard for clinical research sites.

Published 13 May 2026 3 min read

Amavita Research has been awarded GCSA recertification by IAOCR — the International Accrediting Organization for Clinical Research — following the annual recertification assessment completed on 13 May 2026. The recertification confirms that Amavita Research continues to meet the global quality standard for clinical research sites across all 7 business operational areas of the GCSA V5 2024 standard. The certification is valid through 28 February 2027.

What GCSA is

The Global Clinical Site Assessment (GCSA) is the global quality standard for clinical research sites, developed by IAOCR in consultation with sponsors, CROs, public health trial sites, and government organizations. It validates a site's capability through independent assessment against sponsor-defined quality standards. GCSA certification assures sponsors and CROs of operational excellence across the full clinical trial lifecycle.

2026 assessment results

Amavita Research met all 7 modules of the GCSA V5 2024 standard:

Governance and Leadership
Growth and Strategy
Workforce Quality
Participant Engagement
Feasibility
Study Start-Up and Initiation
Study Management, Operations and Close Down

Areas exceeding standards

The 2026 assessment specifically called out two areas where Amavita Research exceeded the GCSA standard:

"A strong commitment to positive participant experiences is evident across the organisation, with staff demonstrating a clear understanding of how this is supported through site procedures and workplace culture. This commitment extends beyond formal policies and is reflected in a shared ethos among staff, strengthening its consistency and impact in practice."

— IAOCR GCSA 2026 Final Report

"A clear and well-defined focus on business development for 2026 is evident. Notable progress has been achieved through the appointment of a new Principal Investigator with expertise in a new therapeutic area (electrophysiology) and access to a new patient population, strengthening the organisation's clinical capabilities and expanding its research offering. In addition, the appointment of a new Head of Growth and Strategy further reinforces the organisation's capacity to deliver its development objectives, supporting a more structured approach to growth and positioning the organisation for future expansion."

— IAOCR GCSA 2026 Final Report

What this means for sponsors

For sponsors evaluating cardiovascular clinical trial sites, GCSA recertification is independent third-party validation that Amavita Research's quality systems, workforce, study operations, and patient engagement continue to meet the global standard. The 2026 recertification reflects ongoing operational maturity, including the recent expansion into cardiac electrophysiology under Dr. Hans C. Rutzen-Lopez and the appointment of Julio G. Martinez-Clark as Head of Growth & Strategy, both of which were specifically recognized in the IAOCR assessment.

About IAOCR

IAOCR — the International Accrediting Organization for Clinical Research — develops and administers global quality standards for clinical research workforce and sites. Learn more at www.iaocr.com.